# Quanterix Corp (QTRX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/quanterix-corp/ JSON: https://steadybase.io/company/quanterix-corp.json Checked Nov 10, 2026. Latest filing read: Sep 11, 2026.

## Company

- Legal name: Quanterix Corp
- Ticker: QTRX (Nasdaq)
- SEC CIK: 0001503274
- Industry: Laboratory Analytical Instruments (SIC 3826)
- Headquarters: Billerica, MA
- Fiscal year ends: December 31
- SEC filer category: Accelerated filer
- Website: quanterix.com
- LinkedIn: https://www.linkedin.com/company/quanterix
- Next earnings date: Nov 9, 2026

## Key facts

- Revenue: $138.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/0001503274-26-000013-index.html
- Operating income: -$125.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/0001503274-26-000013-index.html
- Net income: -$107.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/0001503274-26-000013-index.html
- SG&A: $138.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/0001503274-26-000013-index.html
- Employees: 450 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/qtrx-20251231.htm
- Shares outstanding: 47,478,422 as of Nov 2, 2026 (10-Q filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000043/0001503274-26-000043-index.html
- Auditor: Kpmg LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/qtrx-20251231.htm

## Business

We are a life sciences company transforming healthcare innovation by accelerating biomarker breakthroughs from discovery to diagnostics using our ultra-sensitive translational research and spatial biology instruments, consumables, and services. We continue to invest in pushing a paradigm shift in healthcare from an emphasis on later-stage treatment to a focus on earlier detection, monitoring, prognosis, and, ultimately, prevention.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/qtrx-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $138.9M | -$125.5M | -$107.2M | $138.0M |
| Dec 31, 2024 | $137.4M | -$52.6M | -$38.5M | $101.6M |
| Dec 31, 2023 | $122.4M | -$46.0M | -$28.4M | $89.1M |
| Dec 31, 2022 | $105.5M | -$104.3M | -$99.6M | $91.9M |
| Dec 31, 2021 | $110.6M | -$56.5M | -$55.5M | $92.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/quanterix-corp.json

## Officers and directors

- Everett Cunningham, Chief Executive Officer and joined our board of directors. LinkedIn: https://linkedin.com/in/everettcunningham. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/qtrx-20251231.htm
- Masoud Toloue, President & CEO. Source: Form 4 filed Jan 20, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000186727626000003/0001867276-26-000003-index.htm
- Jason F. Faessler, Chief Financial Officer. Source: Form 4 filed Jul 16, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000214145726000002/0002141457-26-000002-index.htm
- Vandana Sriram, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/vandana-sriram. Source: Form 4 filed Jun 23, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000190822326000010/0001908223-26-000010-index.htm
- Jason Faessler, Chief Financial Officer and Treasurer. LinkedIn: https://www.linkedin.com/in/jason-faessler-8765a81. Source: 8-K filed Jun 9, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000162828026041773/qtrx-20260609.htm
- Anthony Catalano, Chief Operating Officer. Source: 8-K filed May 26, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000150327426000024/qtrx-20260514.htm
- James Edward Gute Jr., Chief Commercial Officer. Source: Form 4 filed Sep 17, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000214827626000002/0002148276-26-000002-index.htm
- Michael Francis Miller, Chief Technology Officer. Source: Form 4 filed Sep 16, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000212051626000017/0002120516-26-000017-index.htm
- Benjamin Meadows, Chief Commercial Officer. Source: Form 4 filed Jun 12, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000214039426000002/0002140394-26-000002-index.htm
- Michael Miller, Chief Technology and Products Officer. Source: 8-K filed May 26, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000150327426000024/qtrx-20260514.htm
- Daniel Char, Chief Legal Officer. LinkedIn: https://linkedin.com/in/danielchar99. Source: Form 3 filed Mar 24, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000175712226000007/0001757122-26-000007-index.htm
- Jeffrey T. Elliott, Board member (per proxy). Source: DEF 14A filed Apr 24, 2026, https://www.sec.gov/Archives/edgar/data/1503274/000110465926048166/tm269763-1_def14a.htm
- David R. Walt, Ph.D., Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm
- Ivana Magovčević-Liebisch, Ph.D., J.D., Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm
- Karen A. Flynn, Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm
- Myla Lai-Goldman, M.D., Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm
- Paul M. Meister, Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm
- Scott Mendel, Board member (per proxy). Source: DEF 14A filed Aug 25, 2025, https://www.sec.gov/Archives/edgar/data/1503274/000110465925082586/tm2521975-3_def14a.htm

## Recent 8-K events

- Aug 10, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000035/qtrx-20260810.htm
- Jun 10, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000028/qtrx-20260609.htm
- Jun 9, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000162828026041773/qtrx-20260609.htm
- May 26, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000024/qtrx-20260514.htm
- May 12, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000162828026034124/qtrx-20260511.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000019/qtrx-20260506.htm
- Mar 2, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/qtrx-20260302.htm
- Jan 8, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000162828026001369/qtrx-20260108.htm
- Nov 20, 2025: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000162828025053420/qtrx-20251120.htm
- Nov 10, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000104/qtrx-20251110.htm

## Insider trades (Form 4)

- Aug 13, 2026: William P. Donnelly (Director) bought 99,400 shares, about $286,354. Source: https://www.sec.gov/Archives/edgar/data/1503274/000120792826000008/0001207928-26-000008-index.htm
- May 12, 2026: Benjamin Meadows (Chief Commercial Officer) bought 3,500 shares, about $9,695. Source: https://www.sec.gov/Archives/edgar/data/1503274/000214039426000002/0002140394-26-000002-index.htm
- Sep 12, 2025: Vandana Sriram (Chief Financial Officer) bought 4,150 shares, about $19,879. Source: https://www.sec.gov/Archives/edgar/data/1503274/000190822325000005/0001908223-25-000005-index.htm

## What management said

- "We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond" Everett Cunningham, President & CEO of Quanterix (8-K filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000042/ex991-qtrxx20260930.htm
- "We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to improve commercial performance, including reorganizing our teams and adding seasoned leadership to sharpen accountability, accelerate execution, and improve operating results in the s" Everett Cunningham, President & CEO of Quanterix (8-K filed Aug 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000035/ex991-qtrxx20260630.htm

## Latest filings

- 8-K filed Aug 10, 2026: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000035/qtrx-20260810.htm
- 10-K filed Mar 2, 2026: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000013/qtrx-20251231.htm
- 10-Q filed Aug 10, 2026: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000036/qtrx-20260630.htm
- DEF 14A filed Apr 24, 2026: https://www.sec.gov/Archives/edgar/data/1503274/000110465926048166/tm269763-1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/